标题
Therapy with oncolytic viruses: progress and challenges
作者
关键词
-
出版物
Nature Reviews Clinical Oncology
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2023-01-11
DOI
10.1038/s41571-022-00719-w
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Combination immunotherapy including OncoVEXmGMCSF creates a favorable tumor immune micro-environment in transgenic BRAF murine melanoma
- (2022) Robyn D. Gartrell et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- NOTCH-Induced MDSC Recruitment after oHSV Virotherapy in CNS Cancer Models Modulates Antitumor Immunotherapy
- (2022) Yoshihiro Otani et al. CLINICAL CANCER RESEARCH
- Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class
- (2022) Howard L. Kaufman et al. Frontiers in Molecular Biosciences
- Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
- (2022) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients
- (2022) Adel Samson et al. Cancer Immunology Research
- Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta-analysis
- (2022) Emma H.A. Stahlie et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- CORE1: Phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).
- (2022) Roger Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial
- (2022) Tomoki Todo et al. NATURE MEDICINE
- PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
- (2022) Andrea Cercek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma
- (2022) Jaime Gállego Pérez-Larraya et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma
- (2022) Jason A. Chesney et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma
- (2022) Neil D. Gross et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective
- (2021) Egle Ramelyte et al. CANCER CELL
- Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma
- (2021) Jianhan Huang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Mutations in the IFNγ-JAK-STAT pathway causing resistance to immune checkpoint inhibitors in melanoma increase sensitivity to oncolytic virus treatment.
- (2021) Tan-Trieu Nguyen et al. CLINICAL CANCER RESEARCH
- Cell death as part of Innate Immunity: cause or consequence?
- (2021) Mario Riera‐Romo IMMUNOLOGY
- Can Biomarkers Guide Oncolytic Virus Immunotherapy?
- (2021) Howard L. Kaufman CLINICAL CANCER RESEARCH
- Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas
- (2021) Gregory K. Friedman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma
- (2021) Georgia M Beasley et al. Journal for ImmunoTherapy of Cancer
- Phase I dose-escalation study of endoscopic intratumoral injection of OBP-301 (Telomelysin) with radiotherapy in oesophageal cancer patients unfit for standard treatments
- (2021) Yasuhiro Shirakawa et al. EUROPEAN JOURNAL OF CANCER
- Real-World Experience of Talimogene Laherparepvec (T-VEC) in Old and Oldest-Old Patients with Melanoma: A Retrospective Single Center Study
- (2021) Johannes Kleemann et al. Cancer Management and Research
- Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience
- (2021) Michael J. Carr et al. ANNALS OF SURGICAL ONCOLOGY
- Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trial
- (2021) R. Dummer et al. NATURE MEDICINE
- Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial
- (2021) E Antonio Chiocca et al. NEURO-ONCOLOGY
- Targeting matrix metalloproteinase MMP3 greatly enhances oncolytic virus mediated tumor therapy
- (2021) Minglong Liang et al. Translational Oncology
- Oncolytic adenovirus targeting TGF-β enhances anti-tumor responses of mesothelin-targeted chimeric antigen receptor T cell therapy against breast cancer
- (2020) Yuxiang Li et al. CELLULAR IMMUNOLOGY
- Real-world use of talimogene laherparepvec in Germany: a retrospective observational study using a prescription database
- (2020) Karly S Louie et al. Future Oncology
- Neoadjuvant checkpoint blockade for cancer immunotherapy
- (2020) Suzanne L. Topalian et al. SCIENCE
- An open-label, single-arm, phase II clinical trial of RP1, an enhanced potency oncolytic herpes virus, combined with nivolumab in four solid tumor types: Initial results from the skin cancer cohorts.
- (2020) Mark R. Middleton et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
- (2020) Myriam Chalabi et al. NATURE MEDICINE
- Immune characterization of metastatic colorectal cancer patients post reovirus administration
- (2020) Ruwan Parakrama et al. BMC CANCER
- Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy
- (2020) Mathilde Feist et al. CANCER GENE THERAPY
- Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST
- (2020) Gregory V. Goldmacher et al. JOURNAL OF CLINICAL ONCOLOGY
- Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer
- (2020) Eva Crespo-Rodriguez et al. Journal for ImmunoTherapy of Cancer
- Clinical landscape of oncolytic virus research in 2020
- (2020) Nicholas Macedo et al. Journal for ImmunoTherapy of Cancer
- A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB–IVM1a Melanoma in Four European Countries
- (2020) Alexander C. J. van Akkooi et al. ADVANCES IN THERAPY
- Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
- (2020) Stephen A Boorjian et al. LANCET ONCOLOGY
- Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment
- (2020) Norihiro Watanabe et al. MOLECULAR THERAPY
- Viral oncolytic immunotherapy in the war on cancer: Infection control considerations
- (2019) Elizabeth V. Robilotti et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience
- (2019) Raphael J. Louie et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Genetically Engineered Cell Membrane Nanovesicles for Oncolytic Adenovirus Delivery: A Versatile Platform for Cancer Virotherapy
- (2019) Peng Lv et al. NANO LETTERS
- Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma
- (2019) Praveen K. Bommareddy et al. OncoImmunology
- Optimizing oncolytic virotherapy in cancer treatment
- (2019) Kevin Harrington et al. NATURE REVIEWS DRUG DISCOVERY
- Combination of Cetuximab and Oncolytic Virus Canerpaturev Synergistically Inhibits Human Colorectal Cancer Growth
- (2019) Zhiwen Wu et al. Molecular Therapy-Oncolytics
- Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
- (2019) Robert H. I. Andtbacka et al. Journal for ImmunoTherapy of Cancer
- Graphene oxide arms oncolytic measles virus for improved effectiveness of cancer therapy
- (2019) Mao Xia et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial
- (2019) Keri A. Streby et al. MOLECULAR THERAPY
- Development of a Nursing Policy for the Administration of an Oncolytic Virus in the Outpatient Setting
- (2019) Vania Hom et al. Seminars in Oncology Nursing
- Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study
- (2019) Devalingam Mahalingam et al. CLINICAL CANCER RESEARCH
- Intratumoral Immunotherapy—Update 2019
- (2019) Omid Hamid et al. ONCOLOGIST
- Oncorine, the World First Oncolytic Virus Medicine and its Update in China
- (2018) Min Liang CURRENT CANCER DRUG TARGETS
- Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma
- (2018) Frederick F. Lang et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
- (2018) Jason Chesney et al. JOURNAL OF CLINICAL ONCOLOGY
- Establishment and genomic characterizations of patient-derived esophageal squamous cell carcinoma xenograft models using biopsies for treatment optimization
- (2018) Jianling Zou et al. Journal of Translational Medicine
- Recurrent Glioblastoma Treated with Recombinant Poliovirus
- (2018) Annick Desjardins et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma
- (2018) Devalingam Mahalingam et al. Cancers
- The advent of oncolytic virotherapy in oncology: The Rigvir® story
- (2018) Pēteris Alberts et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy
- (2018) Carmela Passaro et al. CLINICAL CANCER RESEARCH
- MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation
- (2018) Praveen K. Bommareddy et al. Science Translational Medicine
- Targeted agents and immunotherapies: optimizing outcomes in melanoma
- (2017) Jason J. Luke et al. Nature Reviews Clinical Oncology
- An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non–muscle-invasive bladder cancer: Interim results
- (2017) Vignesh T. Packiam et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- A practical guide to the handling and administration of talimogene laherparepvec in Europe
- (2017) Kevin Harrington et al. OncoTargets and Therapy
- Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials
- (2017) Howard L. Kaufman et al. Journal for ImmunoTherapy of Cancer
- Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection
- (2017) Rocio Garcia-Carbonero et al. Journal for ImmunoTherapy of Cancer
- Combination immunotherapy: a road map
- (2017) Patrick A. Ott et al. Journal for ImmunoTherapy of Cancer
- Combining Oncolytic Adenovirus with Radiation—A Paradigm for the Future of Radiosensitization
- (2017) Sean M. O’Cathail et al. Frontiers in Oncology
- Immune System, Friend or Foe of Oncolytic Virotherapy?
- (2017) Anna C. Filley et al. Frontiers in Oncology
- Oncolytic virus therapy: A new era of cancer treatment at dawn
- (2016) Hiroshi Fukuhara et al. CANCER SCIENCE
- Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma
- (2016) Robert H. I. Andtbacka et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
- (2016) Igor Puzanov et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
- (2016) Naiyer A. Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- A novel, polymer-coated oncolytic measles virus overcomes immune suppression and induces robust antitumor activity
- (2016) Kaname Nosaki et al. Molecular Therapy-Oncolytics
- Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors
- (2015) Miguel A. Villalona-Calero et al. CANCER
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Encapsulated Stem Cells Loaded With Hyaluronidase-expressing Oncolytic Virus for Brain Tumor Therapy
- (2015) Jordi Martinez-Quintanilla et al. MOLECULAR THERAPY
- Oncolytic viruses: a new class of immunotherapy drugs
- (2015) Howard L. Kaufman et al. NATURE REVIEWS DRUG DISCOVERY
- A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: A Children's Oncology Group Phase I Consortium report
- (2015) E . Anders Kolb et al. PEDIATRIC BLOOD & CANCER
- A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
- (2014) D. W. Sborov et al. CLINICAL CANCER RESEARCH
- A Phase 1 Trial of Oncolytic HSV-1, G207, Given in Combination With Radiation for Recurrent GBM Demonstrates Safety and Radiographic Responses
- (2014) James M Markert et al. MOLECULAR THERAPY
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- (2014) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- From Scourge to Cure: Tumour-Selective Viral Pathogenesis as a New Strategy against Cancer
- (2014) Carolina S. Ilkow et al. PLoS Pathogens
- Activated Ras Signaling Pathways and Reovirus Oncolysis: An Update on the Mechanism of Preferential Reovirus Replication in Cancer Cells
- (2014) Jun Gong et al. Frontiers in Oncology
- Combination Treatment of Human Pancreatic Cancer Xenograft Models with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib and Oncolytic Herpes Simplex Virus HF10
- (2013) Kazuo Yamamura et al. ANNALS OF SURGICAL ONCOLOGY
- Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in V600D/EBRAF mutant melanoma depends on JNK and TNF-α signaling
- (2013) J N Kyula et al. ONCOGENE
- Macrophage Delivery of an Oncolytic Virus Abolishes Tumor Regrowth and Metastasis after Chemotherapy or Irradiation
- (2012) M. Muthana et al. CANCER RESEARCH
- Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses
- (2012) K-W Peng et al. GENE THERAPY
- REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors
- (2012) Don G. Morris et al. INVESTIGATIONAL NEW DRUGS
- A First in Human Phase 1 Study of CG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder Cancer
- (2012) James M. Burke et al. JOURNAL OF UROLOGY
- Reovirus: A Targeted Therapeutic--Progress And Potential
- (2012) R. Maitra et al. MOLECULAR CANCER RESEARCH
- Oncolytic virotherapy
- (2012) Stephen J Russell et al. NATURE BIOTECHNOLOGY
- Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
- (2012) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of Macrophages to Target Therapeutic Adenovirus to Human Prostate Tumors
- (2011) M. Muthana et al. CANCER RESEARCH
- Phase I/II Study of Oncolytic HSVGM-CSF in Combination with Radiotherapy and Cisplatin in Untreated Stage III/IV Squamous Cell Cancer of the Head and Neck
- (2010) K. J. Harrington et al. CLINICAL CANCER RESEARCH
- Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics
- (2010) K.J. Harrington et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mesenchymal Stem Cell Carriers Protect Oncolytic Measles Viruses from Antibody Neutralization in an Orthotopic Ovarian Cancer Therapy Model
- (2009) E. K. Mader et al. CLINICAL CANCER RESEARCH
- Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma
- (2009) Neil N. Senzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Recombinant Human Granulocyte-macrophage Colony-stimulating Factor (GM-CSF, Sargramostim) Administered for 3 Years as Adjuvant Therapy of Stages II(T4), III, and IV Melanoma
- (2009) Lynn E. Spitler et al. JOURNAL OF IMMUNOTHERAPY
- Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus
- (2008) J. Qiao et al. CLINICAL CANCER RESEARCH
- Effect of Preexisting Immunity on Oncolytic Adenovirus Vector INGN 007 Antitumor Efficacy in Immunocompetent and Immunosuppressed Syrian Hamsters
- (2008) D. Dhar et al. JOURNAL OF VIROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now